Calistoga Pharmaceuticals Announces Positive Clinical Results from Ongoing Single-Agent and Combination Trials of CAL-101 in Patients with Hematologic Malignancies

SEATTLE--(BUSINESS WIRE)--Calistoga Pharmaceuticals, Inc., the leader in the development of delta-isoform-selective phosphatidylinositol 3-kinase (PI3K) inhibitors for the treatment of cancer and inflammatory diseases, today announced updated data from an ongoing single-agent trial and the first data from a combination trial of CAL-101, the company’s oral, delta-isoform-selective PI3K inhibitor. These clinical results demonstrate the clinical potential of CAL-101, as a single agent and in combination with other standard-of-care therapies, as treatment for patients with hematologic malignancies that have relapsed or are refractory to existing treatments. In addition, pharmacokinetic data and preclinical data characterizing the pharmacological properties of CAL-101 were presented, adding to the growing body of evidence regarding CAL-101’s antitumor effects. The findings were presented during oral and poster presentations at the 52nd American Society of Hematology Annual Meeting in Orlando, FL.